NCT05390619Unknown不适用
Comparison of Different Doses of Verteporfin Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- The complete absorption rate of subretinal fluid
研究概览
简要总结
This is a prospective, randomized and controlled clinical trial of photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). The patients who met the inclusion criteria were randomly divided into 50% dose PDT treatment group and 70% dose PDT treatment group. The primary treatment success rate and adverse event rate of the two groups were compared by optical coherence tomography (OCT), and then the best PDT treatment scheme for chronic CSC was summarized.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-75 years old, regardless of gender;
- •Meet the diagnostic criteria of central serous chorioretinopathy;
- •The course of CSC (subject to the symptoms of this disease) is more than 3 months;
- •Patients with simultaneous diseases of both eyes were included in those with more subretinal fluid.
排除标准
- •macular neuroretinal detachment caused by rhegmatogenous retinal detachment, uveitis, age-related macular degeneration, polypoid choroidal angiopathy and other fundus diseases;
- •a previous history of PDT treatment;
- •systemic hormone or local hormone nasal spray is being used, or hormone is stopped for less than 3 months.
结局指标
主要结局
The complete absorption rate of subretinal fluid
时间窗: 3 months after the primary PDT
The absorption of subretinal fluid was observed on optical coherence tomography at each follow up visit
次要结局
- Best corrected visual acuity change after the PDT(12 months after the PDT)
- Subfoveal choroidal thickness change after the PDT(12 months after the PDT)
- Central foveal thickness change after the PDT(12 months after the PDT)
研究者
Yao Yiou
Principal Investigator
Peking University People's Hospital
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal NeovascularizationSubfoveal Choroidal NeovascularizationNCT00930189Asociación para Evitar la Ceguera en México
进行中（未招募）
1 期
A Phase 1 Trial of Verteporfin Photodynamic Therapy in Unresectable Pancreatic Carcinoma (VERTPAC-01 study) - VERTPAC-01EUCTR2006-004097-28-GBniversity College Hospitals NHS Foundation Trust/ University College London12
终止
2 期
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)Macular DegenerationChoroidal NeovascularizationNCT00433017Novartis255
已完成
3 期
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal NeovascularizationMacular DegenerationChoroidal NeovascularizationNCT00436553Novartis321
Enrolling By Invitation
4 期
Hematoporphyrin Photodynamic Therapy for Esophageal CancerPhotodynamic TherapyEsophageal CancerNCT06437288Sun Yat-sen University198